Literature DB >> 17118626

Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication.

Ayelet Meron Ruscio1, Wai Tat Chiu, Peter Roy-Byrne, Paul E Stang, Dan J Stein, Hans-Ulrich Wittchen, Ronald C Kessler.   

Abstract

Concerns have been raised that the DSM-IV requirements of 6-month duration, excessive worry, and three associated symptoms exclude a substantial number of people with clinically significant anxiety from a diagnosis of generalized anxiety disorder (GAD). We examined the implications of relaxing these three criteria for the estimated prevalence and predictive validity of GAD using nationally representative data from the US National Comorbidity Survey Replication. Relaxing all three criteria more than doubles the estimated prevalence of GAD. Broadly defined GAD significantly predicts the subsequent first onset of a wide range of temporally secondary disorders. The odds of secondary disorders are somewhat smaller for broadly defined than DSM-IV GAD, though few of these differences are statistically significant. Results suggest that subthreshold manifestations of GAD are significantly related to elevated risk of subsequent psychopathology. Further research is needed to determine whether broadening the current diagnostic criteria results in a more valid characterization of GAD.

Entities:  

Mesh:

Year:  2006        PMID: 17118626      PMCID: PMC2475335          DOI: 10.1016/j.janxdis.2006.10.004

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  35 in total

1.  The US National Comorbidity Survey Replication (NCS-R): design and field procedures.

Authors:  Ronald C Kessler; Patricia Berglund; Wai Tat Chiu; Olga Demler; Steven Heeringa; Eva Hiripi; Robert Jin; Beth-Ellen Pennell; Ellen E Walters; Alan Zaslavsky; Hui Zheng
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

2.  The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI).

Authors:  Ronald C Kessler; T Bedirhan Ustün
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

3.  Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Deborah S Hasin; Frederick S Stinson; Deborah A Dawson; W June Ruan; Risë B Goldstein; Sharon M Smith; Tulshi D Saha; Boji Huang
Journal:  Psychol Med       Date:  2005-10-05       Impact factor: 7.723

4.  Should excessive worry be required for a diagnosis of generalized anxiety disorder? Results from the US National Comorbidity Survey Replication.

Authors:  Ayelet Meron Ruscio; Michael Lane; Peter Roy-Byrne; Paul E Stang; Dan J Stein; Hans-Ulrich Wittchen; Ronald C Kessler
Journal:  Psychol Med       Date:  2005-12       Impact factor: 7.723

5.  Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Nancy Brandenburg; Michael Lane; Peter Roy-Byrne; Paul D Stang; Dan J Stein; Hans-Ulrich Wittchen
Journal:  Psychol Med       Date:  2005-07       Impact factor: 7.723

6.  Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients.

Authors:  Robert A Schoevers; D J H Deeg; W van Tilburg; A T F Beekman
Journal:  Am J Geriatr Psychiatry       Date:  2005-01       Impact factor: 4.105

7.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

8.  The National Comorbidity Survey Replication (NCS-R): background and aims.

Authors:  Ronald C Kessler; Kathleen R Merikangas
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

9.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01

10.  Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being.

Authors:  Gavin Andrews; Tim Slade; Cathy Issakidis
Journal:  Br J Psychiatry       Date:  2002-10       Impact factor: 9.319

View more
  34 in total

1.  The increase in interest in GAD: Commentary on Asmundson & Asmundson.

Authors:  Michelle G Newman; Amy Przeworski
Journal:  J Anxiety Disord       Date:  2018-05

Review 2.  Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.

Authors:  Katja Beesdo; Susanne Knappe; Daniel S Pine
Journal:  Psychiatr Clin North Am       Date:  2009-09

3.  Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristics.

Authors:  M Burstein; K Beesdo-Baum; J-P He; K R Merikangas
Journal:  Psychol Med       Date:  2014-01-02       Impact factor: 7.723

Review 4.  The Effects of Resistance Exercise Training on Anxiety: A Meta-Analysis and Meta-Regression Analysis of Randomized Controlled Trials.

Authors:  Brett R Gordon; Cillian P McDowell; Mark Lyons; Matthew P Herring
Journal:  Sports Med       Date:  2017-12       Impact factor: 11.136

Review 5.  Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

Authors:  Siegfried Kasper; Markus Gastpar; Walter E Müller; Hans-Peter Volz; Hans-Jürgen Möller; Angelika Dienel; Sandra Schläfke
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 6.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment.

Authors:  Michelle G Newman; Sandra J Llera; Thane M Erickson; Amy Przeworski; Louis G Castonguay
Journal:  Annu Rev Clin Psychol       Date:  2013       Impact factor: 18.561

8.  Implications of modifying the duration requirement of generalized anxiety disorder in developed and developing countries.

Authors:  S Lee; A Tsang; A M Ruscio; J M Haro; D J Stein; J Alonso; M C Angermeyer; E J Bromet; K Demyttenaere; G de Girolamo; R de Graaf; O Gureje; N Iwata; E G Karam; J-P Lepine; D Levinson; M E Medina-Mora; M A Oakley Browne; J Posada-Villa; R C Kessler
Journal:  Psychol Med       Date:  2008-12-18       Impact factor: 7.723

Review 9.  Anxiety disorders in pregnancy.

Authors:  Bavanisha Vythilingum
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

10.  The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys.

Authors:  Ronald C Kessler; Sergio Aguilar-Gaxiola; Jordi Alonso; Somnath Chatterji; Sing Lee; Johan Ormel; T Bedirhan Ustün; Philip S Wang
Journal:  Epidemiol Psichiatr Soc       Date:  2009 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.